EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, RepliCel Life Sciences's Enterprise Value is $2.63 Mil.
RepliCel Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.47 Mil. Therefore, RepliCel Life Sciences's EV-to-FCF for today is -1.79.
The historical rank and industry rank for RepliCel Life Sciences's EV-to-FCF or its related term are showing as below:
REPCF'
s EV-to-FCF Range Over the Past 10 Years
Min: -162.61 Med: -3.42 Max: 84.68
Current: -1.8
During the past 13 years, the highest EV-to-FCF of RepliCel Life Sciences was 84.68. The lowest was -162.61. And the median was -3.42.
REPCF's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 8.34
vs REPCF: -1.80
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of RepliCel Life Sciences's EV-to-FCF
For the Biotechnology subindustry, RepliCel Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RepliCel Life Sciences's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RepliCel Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where RepliCel Life Sciences's EV-to-FCF falls into.
RepliCel Life Sciences's current Enterprise Value is $2.63 Mil.
RepliCel Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RepliCel Life Sciences (OTCPK:REPCF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
RepliCel Life Sciences's PE Ratio for today is calculated as:
RepliCel Life Sciences's share price for today is $0.04284.
RepliCel Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
RepliCel Life Sciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of RepliCel Life Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
RepliCel Life Sciences (RepliCel Life Sciences) Business Description
RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from Licensing fees.
RepliCel Life Sciences (RepliCel Life Sciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
REPCF has been successfully added to your 